Celiac disease (CD) is a chronic, immune-mediated disorder in which ingestion of gluten-containing grains (wheat, barley, and rye) triggers small-bowel inflammation and villous atrophy. The condition is best understood as an autoimmune enteropathy, with a characteristic genetic association (HLA-DQ2 and HLA-DQ8) and a primary target of intestinal mucosa. In most individuals, symptoms arise from both malabsorption due to mucosal injury and immune activation that perpetuates inflammation even when dietary gluten exposure is intermittent.
Mechanistically, gluten peptides are deamidated by tissue transglutaminase (tTG), increasing their affinity for HLA-DQ2 or HLA-DQ8 on antigen-presenting cells. This enhanced antigen presentation drives activation of gluten-specific CD4+ T lymphocytes and subsequent inflammatory cascades, including cytokine release and recruitment of additional immune effectors. A hallmark of CD is the formation of autoantibodies—particularly anti-tTG immunoglobulin A (IgA)—that serve as diagnostic biomarkers. Histologically, CD is characterized by intraepithelial lymphocytosis (often with a villous atrophy pattern) and crypt hyperplasia. The severity of mucosal damage can vary, influencing clinical presentation from classic malabsorptive syndromes to subtle or extraintestinal manifestations.
Clinically, CD is heterogeneous. Classic presentations include chronic diarrhea, weight loss, abdominal distension, and nutritional deficiencies such as iron-deficiency anemia and fat-soluble vitamin deficiencies. However, many patients present without overt gastrointestinal symptoms. Extraintestinal features include dermatitis herpetiformis, elevated transaminases due to hepatic involvement, osteopenia or osteoporosis from impaired calcium absorption, neurologic complications (e.g., ataxia, neuropathy), and reproductive issues such as infertility or recurrent pregnancy loss. Children may show growth delay, delayed puberty, irritability, and behavioral changes. The variability is partly explained by differences in immune response, baseline mucosal integrity, gluten exposure patterns, and coexisting conditions.
Diagnosis requires a structured approach. Serologic testing typically begins with anti-tTG IgA, accompanied by total serum IgA to exclude IgA deficiency, in which case anti-deamidated gliadin peptide (DGP) IgG may be used. Positive serology suggests CD but does not replace confirmatory evaluation. Current clinical practice generally uses upper endoscopy with small-bowel biopsies to assess for villous atrophy and intraepithelial lymphocytosis, using standardized histopathologic criteria. Importantly, testing accuracy depends on ongoing gluten consumption; starting a gluten-free diet before evaluation can lead to false-negative results by reducing immunologic stimulation and mucosal changes.
Differential diagnosis includes other causes of villous atrophy or malabsorption, such as common variable immunodeficiency, autoimmune enteropathy, giardiasis, tropical sprue, and medication-associated enteropathy. Distinguishing CD is critical because management involves strict dietary adherence, potential monitoring of deficiencies and comorbidities, and counseling to reduce accidental gluten exposure.
Management is diet-centered and disease-modifying. Lifelong adherence to a gluten-free diet (GFD) is the cornerstone, aiming to eliminate immune triggers and allow mucosal healing. Many patients experience symptomatic improvement within weeks to months, while histologic recovery may take longer. Persistent symptoms after GFD can reflect ongoing gluten exposure, refractory CD (rare), or alternative diagnoses. Nutritional assessment is essential, with correction of iron, folate, vitamin B12, vitamin D, calcium, and other micronutrient deficiencies based on clinical findings and laboratory results.
Monitoring includes repeat serology to track decline in anti-tTG titers, assessment of symptom resolution, and surveillance for associated conditions such as osteoporosis and malignancy risk, particularly in those with untreated or refractory disease. Patients should also be educated about cross-contamination risks and labeling practices. In dermatitis herpetiformis, a GFD can improve skin symptoms, though dapsone may be used short term for rapid control while awaiting dietary response.
When symptoms persist despite good adherence, clinicians consider refractory CD, categorized into two forms based on immune phenotype (usually not responding to conventional management). Treatment strategies in refractory cases may involve immunosuppressive therapies under specialist supervision. Ongoing research is exploring targeted therapies that modulate the immune response to gluten peptides, improve diet tolerability, or reduce antigenicity without requiring complete dietary elimination.
In summary, celiac disease is an immune-driven gluten-sensitive enteropathy with defined serologic and histologic correlates, guided by genetic susceptibility and driven by tTG-mediated gluten peptide presentation. Accurate diagnosis requires maintaining gluten intake during testing, and effective management depends on strict, lifelong gluten avoidance with monitoring for nutritional deficiencies, comorbidities, and treatment response. Source: @lira_guevara (via X/Twitter post, Jun 20, 2026).
celia susana guevara: $ZERO is only 157 votes away from getting listed on Moonshot Don’t sleep on this and vote asap 👇. #breaking
— @lira_guevara May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
